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Universal Screening for Congenital 
CMV Infection
Sara Lunardi, Francesca Lorenzoni and Paolo Ghirri
Abstract
Congenital cytomegalovirus (CMV) infection is an important public health 
problem. It is a leading cause of disability in children. Congenitally infected neo-
nates often appear asymptomatic at birth or have nonspecific symptoms. An early 
diagnosis and subsequent early antiviral therapy associated to nonpharmacologi-
cal therapy (e.g., hearing rehabilitation, speech-language therapy, and cochlear 
implants) can reduce long-term disability. Much research has been done in this 
field, but further studies are still necessary. Looking back at the most recent papers, 
we will draw a review on this topic trying to answer to the question: could universal 
CMV screening be a useful and cost-effective diagnostic tool?
Keywords: cytomegalovirus, universal screening, congenital infection, hearing loss, 
disability
1. Introduction
Congenital cytomegalovirus (CMV) infection is an important public health 
problem. It is a leading cause of disability in children. Even if it is a major public 
concern and a high cost, there is little awareness among the general public and 
medical officers. Most pregnant women are not aware of CMV and do not know 
how to prevent it. Congenitally infected neonates often appear asymptomatic 
at birth or have nonspecific symptoms. An early diagnosis and subsequent early 
antiviral therapy associated to nonpharmacological therapy (e.g., hearing reha-
bilitation, speech-language therapy, and cochlear implants) can reduce long-term 
disability.
Routine ultrasound scans fail to identify signs of cytomegalovirus infection till 
late gestation. Furthermore, most congenitally infected babies are asymptomatic 
at birth and thus will not be identified by routine clinical examination or hear-
ing test (the majority of neonates with CMV-related sensorineural hearing loss 
will have late onset or progressive losses). Although congenital cytomegalovirus 
infection is more common than most screened newborn conditions, a routine 
cytomegalovirus screening at birth is not performed [1], even if the existence of 
reliable tests to early diagnose the condition, the improved outcomes following 
early diagnosis and the successful antiviral treatment could fulfill the criteria for 
universal screening [2, 3].
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2. Congenital cytomegalovirus infection
2.1 Incidence, transmission routes, and clinical spectrum
The overall CMV seroprevalence in women of childbearing age depends on 
age, parity, ethnicity, and social status; differs between countries and regions; and 
changes over time.
The congenital infection prevalence varies according to the chosen diagnostic 
criteria and how tests are performed by the laboratory. It affects around the 0.5–
0.7% of all live births in industrialized countries such as Western Europe, United 
States, Canada, and Australia. It affects even more babies (1–2% of all live births) in 
other countries such as Africa, Latin America, and most Asian countries [1, 4–11].
Cytomegalovirus (CMV) is a herpesvirus spread by almost all human fluids 
(blood, saliva, breast milk, urine, sperm, and vaginal fluids). Cytomegalovirus usu-
ally leads to unknown infection in immunocompetent adults, and so it happens in 
pregnant women. In Europe, 1–8% of women are exposed to primary infection [12].
Infants and toddlers often shed the virus for months or even years, and pregnant 
women could easily be infected by urine and saliva. Intrauterine infection leads 
to fetal infection with a transmission rate of 32% in primary maternal infection 
and 1.4% in recurrent maternal infection. Consequences are worst if the mother is 
primary infected (10–18% of newborns with symptomatic congenital CMV disease 
at birth and 10–58% rate of permanent and late sequelae), but also secondary 
infection (reactivation by a preexistent herpesvirus or infection by a new strand) 
can lead to neurological sequelae (8% circa of late sequelae) [12]. Due to the high 
overall prevalence, two-thirds of babies with congenital CMV infections are born to 
mothers with preexistent antibodies [13].
The clinical spectrum of congenital CMV varies from the absence of signs 
(85–90% of infected neonates are asymptomatic) to potentially life-threatening 
disease (10–15% are symptomatic at birth with a wide spectrum of disease expres-
sion: clinical manifestations may include sensorineural hearing loss, hepatomegaly, 
jaundice, petechiae, microcephaly, chorioretinitis, and intrauterine growth restric-
tion) [14].
In Europe, congenital cytomegalovirus infection is a leading cause of neurologi-
cal disabilities in children such as sensorineural hearing loss (it is the main cause of 
nongenetic sensorineural hearing loss), blindness, neurodevelopment delays, and 
cerebral palsy. Permanent impairments mainly target the central nervous system.
Hearing loss may be present at birth or has a delayed onset. About 50% of 
sensorineural hearing loss further deteriorates during childhood [14]. At present, 
no definite markers have been identified to predict which infants with mild signs or 
asymptomatic disease will develop sensorineural hearing loss: viral load as deter-
mined by polymerase chain reaction could probably be useful for this purpose [15].
Even if congenital cytomegalovirus infection is a major public concern and a 
high cost, there is little awareness among the general public and medical officers.
While cytomegalovirus is a routine test for pregnant women in eight European 
countries and Israel, it is not a mandatory test in Italy and most obstetrics do not rec-
ommend it [16, 17] probably due to lack of definite and universally accepted interven-
tion for pregnant women with a primary infection and to the fact that most infected 
babies are born to mothers experiencing a nonprimary maternal infection [14].
2.2 Diagnostic timing
Routine ultrasound scans fail to identify signs of cytomegalovirus infection till 
late gestation. Furthermore, most congenitally infected babies are asymptomatic 
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at birth and thus will not be identified by routine clinical examination or hearing 
test (the majority of neonates with CMV-related sensorineural hearing loss will 
have late onset or progressive losses). Early, reliable, and relatively inexpensive tests 
should be defined in order to identify these babies at risk at an early stage.
To make diagnosis of congenital infection, tests should be performed within the 
first 2–3 weeks of age. The Joint Committee on Infant hearing states that all babies 
with hearing loss of uncertain origin, based on an initial evaluation, should be 
tested for cytomegalovirus [18].
But if CMV diagnosis is reliable and if the test is performed within the first 
3 weeks of age, then waiting for a complete audiological and medical evaluation 
often means that it is too late to diagnose congenital CMV infection.
2.3 Universal screening: pro and cons
According to the American College of Medical Genetics Newborn Screening 
Expert Group “To be included as a primary target condition in a newborn screening 
program, a condition should meet the following minimum criteria: It can be identi-
fied at a period of time (24 to 48 hours after birth) at which it would not ordinarily 
be clinically detected, a test with appropriate sensitivity and specificity is avail-
able, there are demonstrated benefits of early detection, timely intervention, and 
efficacious treatment” [19]. Earlier on the Wilson and Jungner criteria for newborn 
screening had stated that the condition should represent a public health problem 
and a well-known condition, a suitable test should exist to early diagnose it and the 
benefit should outweigh the risks and costs of early intervention [20, 21].
Although congenital cytomegalovirus infection is more common than most 
screened newborn conditions, a routine cytomegalovirus screening at birth is not 
performed [1], even if the existence of reliable tests to early diagnose the condition, 
the improved outcomes following the early diagnosis and the successful antiviral 
treatment could fulfill the criteria for universal screening [2, 3].
In Italy, the prevalence of congenital CMV infection is lower than other coun-
tries (0.15–0.51% according to Italian Higher Health Institute data) but still higher 
than other conditions that are routinely screened at birth (e.g., cystic fibrosis that 
occurs in about one over 2500–3000 healthy neonates, phenylketonuria with an 
incidence of 1:10.000 newborns, or congenital hypothyroidism with a prevalence of 
1/2000–4000).
According to the informal International Congenital Cytomegalovirus 
Recommendations Group that convened in 2015, “consideration must be given to 
universal neonatal screening for cytomegalovirus to facilitate early detection and 
intervention for sensorineural hearing loss and developmental delay” [22].
Cannon et al. in a study published in 2014 estimated the number of babies with 
the most common CMV-related disabilities (such as hearing loss, visual impair-
ment, and cognitive deficits) in the United States. For each disability, they analyzed 
the existence of useful therapeutic intervention. They found evidence of benefits 
of nonpharmacological treatments in babies with cognitive deficits and in babies 
with delayed hearing loss with onset within the first 2 years of age. No benefits were 
found for babies with visual impairment [23]. Improved language development 
should result by a prompt detection and management of late onset hearing loss 
(e.g., use of hearing aids or cochlear implants).
The economic burden caused by congenital CMV is substantial as many affected 
babies require ongoing care, special therapeutic, and educational services [23].
Congenital CMV disease (cCMVd) is associated with a substantial economic 
burden, not only at birth and throughout the first year of life, but also during child-
hood, adolescence, and adulthood. Although a lot has been published about the 
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clinical outcomes and sequelae associated with congenital CMV infection, less data 
are available regarding health care resource utilization and costs associated with 
cCMVd.
The Committee to Study Priorities for Vaccine Development estimated in 2000 
that there were 40,000 infants born every year in the United States with CMV 
infection and assumed 400 deaths annually from the congenitally acquired CMV 
infection and about 8000 children with permanent disabilities [24]. Assuming that 
these children require diagnostics, hospitalization, long-term care such as regular 
visits to a specialist for the lifetime and special schooling expense, the estimated 
annual direct economic cost for caring for these children was estimated at about 1–2 
billion dollars [14, 24, 25]. Lifetime costs of hearing impairment are available, and 
in 2007, costs including devices, medical costs, special education, and lost produc-
tivity were estimated to be over 700.000 euro per person with bilateral hearing 
impairment [20].
Ronchi et al. defined congenital CMV infection a huge public health prob-
lem with an estimated annual cost of up to 4 billion dollars in the United States 
alone [26].
A recent study by Clinthera et al., in line with previously published US data, 
revealed inpatient costs associated with cCMVd in infants. They focused on birth 
admission describing a mean long of stay (LOS) between 22.1 and 37.5 days with 
mean costs between $46,994 and $98,126, corresponding to accrue costs at birth 
about 1.5–2.1 times greater than control infants for cesarean and vaginal deliver-
ies. Moreover, during the first year of life, infants with cCMVd had costs about 7 
times greater than control infants. The key cost driver among the cCMVd popula-
tion is represented by inpatient visits. Beyond the direct economic impact, other 
aspects of congenital CMV (cCMV) infection affect both the patient and the 
society. In the same study, the annual economic costs, both direct and indirect, 
associated with care of children with disabilities due to cCMV infection (hearing 
loss and cognitive disabilities), range between $20,000 and $60,000, with an 
average of $30,000 per family [27].
Both universal screening and targeted screening have shown to be cost-effective, 
but the first one probably provides large net savings and better care [26, 28–29].
As already underlined by Gantt et al., introducing a screening program for 
cCMV at birth would allow for identification of asymptomatic newborns with 
cCMV, who would previously have gone undiagnosed and provide potentially early 
treatment and ongoing neurodevelopmental monitoring, including hearing surveil-
lance. With their well-designed cost-effectiveness study, they provide key support 
for the healthcare system benefits, especially cost savings, for either a targeted or 
universal approach to screening cCMV. The potential benefits described by this 
study, in particular those provided by universal screening, when loss of produc-
tivity costs is taken into account, make it the most attractive form of screening, 
compared to targeted screening [30].
Among all infants born in the United States, identification of 1 case of cCMV 
infection by universal screening was estimated to cost $2000 to $10,000 and by 
targeted screening, $566 to $2832. Net savings from universal screening were esti-
mated to be greater than those from targeted screening, although screening costs 
are higher. Savings from screening strategies are derived not only from improved 
hearing with antiviral treatment of affected newborns but also from earlier detec-
tion of late-onset hearing loss [28].
The importance of the economic burden of CMV has started to be recognized 
also in Europe, where a recent Dutch study by Korndewal et al. confirmed that 
children with cCMV have higher average healthcare costs in the first 6 years of life 
than cCMV-negative children. The difference in total healthcare costs between these 
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groups is more than €2500 per child. This study again revealed that the large and 
usually unrecognized groups of children with cCMV who are asymptomatic at birth 
are responsible for half of the costs, underestimating the real impact. Other causes 
of underestimation are the fact that children who died were not included and that 
the evaluation of the costs is only up to 6 years of age, while, at a later follow-up, the 
difference between cCMV-positive and cCMV-negative children might become even 
larger. Finally, other costs related to the impairment of children with cCMV, such 
as special needs education, future reduced productivity, and potential productivity 
loss of parents, were not taken into account [31].
Even in the United Kingdom, a cost model had been proposed, but, due to the 
scarcity of robust data preventing inclusion of many expected costs, it is likely that 
this model underestimates the “true” cost. It estimated that the cost of cCMV to 
the United Kingdom in 2016 was £732 million, of which approximately 40% of the 
costs were direct and 60% indirect. Acute management of cCMV was the lowest 
contributing cost (estimated at £1.2 million), with costs for management of long-
term sequelae being orders of magnitude greater. As well as in the United States, 
also in the United Kingdom, both universal and targeted newborn screening would 
be cost-effective options for detecting and reducing hearing loss and other conse-
quences caused by cCMV [32].
Many studies have already evaluated the benefits of a targeted screening pro-
gram in the United Kingdom. Williams et al. estimated that the cost of “protecting” 
a case of childhood SNHL from cCMV identified and treated through a national 
targeted screening program would be ∼£14,000. In comparison, detailed health 
economic analysis suggests that the societal cost of bilateral hearing impairment 
in children aged 7–9 years rises from £9120 to £21,179 per year from moderate to 
severely affected children, and the lifelong cost of a pediatric cochlear implant is 
£82,000–108,000. The cost of identifying a case of cCMV-related SNHL varied 
between £9224 and £5413, and the cost of “protecting” a case of cCMV-related 
SNHL varied between £19,601 and £11,502, taking into account only the healthcare 
costs and no family and wider societal costs [33].
Based on these economic data, it could be the right time to introduce also in 
Europe a universal screening program even if larger studies to determine the cost-
effectiveness and utility of this policy would be helpful.
Commonsense says that screening should be performed only if potential 
benefits outweigh the costs and potential harms. Potentially negative aspects 
of Universal Screening could be parental stress linked to a positive diagnosis in 
those CMV infected babies who will never develop clinical problems related to 
the congenital infection or costs of unnecessary visits or tests. But, on the other 
hand, a definite diagnosis could reduce parental (and medical) stress and anxiety 
caused by an uncertain diagnosis in babies with nonspecific symptoms (and could 
also save anxiety and costs linked to the diagnostic odyssey that is often linked to 
without-definite-cause late onset hearing or neurological impairment). In studies, 
universal screening has shown to be well accepted by parents. Early diagnosis could 
be important, but it is fundamental that children and parents are not left alone after 
such a diagnosis [23, 34].
2.4 Diagnostic tests
Early, reliable, and relatively inexpensive tests should be defined in order to 
identify these babies at risk at an early stage (Table 1).
Traditional isolation of the virus by culture of urine or saliva is the gold standard 
test, but it is not suitable as a mass screening because it cannot be automated, and 
it is labor- and resource-intensive and requires tissue culture facilities [35]. On the 
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other hand, PCR (real-time polymerase chain reaction) could be automated, and it 
is low cost and does not seem to be affected by sample storage and transport. PCR 
tests could then be suitable as a mass screening and could be performed on urine, 
saliva, and dried blood spot samples. CMV is largely excreted in urine; thus, PCR 
on urine is largely used to diagnose congenital CMV infection with a cost per child 
of about 22 € (based on rough cost estimations by our own facilities). According 
to the study published by Yamaguchi et al. in 2016, quantification of urinary CMV 
load could even predict the incidence of late-onset sensorineural hearing loss 
(SNHL) and neurological disorders because urinary CMV copy number seemed 
to be associated with SNHL and central nervous system damage: CMV viral load 
in urine not only could so be diagnostic of congenital infection but also predict 
sequelae [36]. The problem is that collecting urine for a universal screening could be 
more difficult (and use of cotton balls or filter cards is still to be evaluated in large 
studies) than PCR on saliva.
Dried blood spots (DBS) are already collected routinely for metabolic screen-
ing worldwide and have been suggested as the optimal choice, but according to 
2010 Boppana et al. study [35], CMV testing with DBS real-time PCR compared 
with tests on saliva had low sensitivity, limiting its value as a screening test. Other 
studies reported variable sensitivity of PCR on DBS, probably due both to technical 
Test It could be 
performed 
on
Pro Cons
Traditional isolation 
of the virus by 
culture
Urine Reliable, it is the gold standard to 
diagnose CMV infection.
It is not suitable as 
a mass screening 
because it cannot 
be automated, and 
it is labor- and 
resource-intensive 
and requires tissue 
culture facilities.
Saliva
PCR (real-time 
polymerase chain 
reaction)
Urine PCR could be 
automated, 
and it is low 
cost and does 
not seem to 
be affected by 
sample storage 
and transport.
CMV is largely 
excreted in urine, 
and quantification 
of urinary CMV 
load could even 
predict the 
incidence of late-
onset sequelae.
Collecting urine 
for a universal 
screening could be 
difficult.
Saliva Saliva swabs are 
easy to collect.
False positive 
results could 
be related to 
contamination by 
CMV in maternal 
milk.
Dried 
blood spot 
samples
It could be useful 
for retrospective 
diagnosis in late-
onset hearing loss.
Studies reported 
variable sensitivity 
of PCR on DBS.
Detection of 
CMV specific 
immunoglobulin M 
antibodies
Neonatal 
serum
— Only 20–70% of 
infected neonates 
show specific IgM
Table 1. 
Diagnostic tests.
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issues and to the fact that not all congenitally infected neonates have detectable 
viremia at birth. For this reason, it is not suitable for universal screening but could 
be useful for retrospective diagnosis in late onset hearing loss (even if a positive test 
is diagnostic while a negative test does not rule out a congenital CMV infection). 
Detection of CMV specific immunoglobulin M antibodies in neonatal serum may 
as well disclose congenital infection, but only 20–70% of infected neonates show 
specific IgM [37].
In a multicenter screening study published on New England Journal of Medicine 
in 2011, Boppana et al. concluded that PCR assays of both liquid and dried saliva 
showed high sensitivity and specificity and could be used as a potential screening 
test for congenital CMV infection. The rate of false positive results in both swabs 
was less than 0.03%: in case of positive test, a confirmation test within 3 weeks of 
age could then rule out a false positive result [14, 38]. Barkai et al. concluded in 
their report of clinical experience [39] that universal CMV screening using real-
time PCR saliva is a feasible and easy-to-use method for newborn infants.
The ease of saliva swab collection makes the PCR on saliva the preferred test 
for newborn screening (probably with costs similar to those of PCR on urine), but 
if the test gives a positive result, then confirmation should be obtain by PCR or 
culture test on urine in order to rule out false positive results due, for example, to 
contamination by CMV in maternal milk.
2.5 Antiviral therapy
The treatment of symptomatic congenital CMV infection with intravenous 
ganciclovir for 6 weeks has shown to improve audiological outcome at 6 months. 
Treated infants had fewer development delays than untreated babies according 
to Denver Developmental evaluation. The Collaborative Antiviral Study Group 
determined the dose of oral valganciclovir resulting in systemic exposure similar to 
that with intravenous ganciclovir, so that actually therapy with intravenous gan-
ciclovir or oral valganciclovir for 6 weeks is an accepted therapy for symptomatic 
CMV [40–42]. Given that the results seemed to wane after 2 years of age, a recent 
study [2] was performed by Kimberlin et al. in 2015 comparing the 6 weeks versus 
a 6-month therapy. It concluded that treating the condition with oral valganciclovir 
(16 mg/kg/dose twice a day) for 6 months appeared to improve developmental and 
hearing outcomes in the longer term: this is now considered an effective and well-
tolerated therapeutic option for symptomatic neonates, while currently evidence of 
benefit of antiviral therapy in asymptomatic babies is still lacking [14] (Table 2). 
Asymptomatic babies are the majority of congenital CMV infected neonates, and 
since these babies are at risk of late-onset sequelae, further studies are needed in 
order to define the best pharmacological and nonpharmacological strategies. For 
these babies, a universal screening would be fundamental for an early diagnosis 
as early rehabilitation treatments are vital. Symptomatic neonates, instead, would 
probably not benefit of a screening program (for example, they would probably be 
already detected by universal hearing screening), apart from the advantages of a 
more immediate diagnosis with consequent parental and physician peace of mind.
2.6 Prevention
Handwashing and other preventive measures to avoid contact with potentially 
contaminated body fluids are likely to be effective in preventing seroconversion in 
pregnant women [12]. Toddlers can shed the virus through saliva and urine for a 
long period of time, so women dealing with young children are at particular risk. 
Most women have not ever heard of CMV infection.
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Of 643 women surveyed by Jeon et al. in their study published in 2006 [43], 
only 22% had heard of congenital CMV, while in a national mail survey of the US 
population, only 14% of female respondents had heard of CMV [44].
In our Neonatal Units (University Hospital of Pisa and S Luca Hospital of 
Lucca), we just started a survey asking mothers of healthy term newborns if they 
had ever heard of CVM (first question), if they knew their CMV status (second 
question), and if they knew how to prevent CMV infection (third question). From 
the few data we have collected since, 65% of women had somewhere heard of CMV, 
but 82% did not know their CMV status, and, most importantly, 90% of women did 
not know how to prevent CMV infection.
Information should be given to all women of reproductive age about simple 
hygiene measures and change of behavior that could prevent seroconversion. 
All women who are pregnant or planning to become pregnant should be fully 
informed, especially if dealing with children. They should be educated about 
hygienic practices to reduce the risk of CMV infection, assuming that all toddlers 
and young children could be secreting the virus through saliva and urine. Hygienic 
measures include not only hand washing with soap after activities such as changing 
diapers, bathing or feeding a baby, wiping running nose, touching baby’s toys, or 
surfaces contaminated by saliva or urine, but also avoiding kissing babies on the 
mouth, sharing kitchen utensils, toothbrushes, or towels [25] (Table 3).
In 2015, Revello et al. published a mixed interventional and observational con-
trolled study to measure the effectiveness of hygiene information among pregnant 
seronegative women at risk of primary CMV infection: 1.2% of women who had 
been given hygiene information at 11–12 weeks of gestation seroconverted versus 
7.6% in the comparison group, and three newborns were diagnosed with congenital 
infection in the intervention group versus eight neonates in the group of women 
who had not been informed [45].
3. Conclusion
It is difficult to estimate, on the basis of precise numbers, the potential benefit of 
a congenital CMV screening, and surely further studies are urgently needed, but we 
could probably say that it could be an useful tool for an early intervention on those 
babies whose congenital infection would have never been detected at an early stage 
on a clinical basis. The main value of a universal screening is to pick up congeni-
tally infected babies who are asymptomatic or with mild symptoms unrevealed 
• Assume that all toddlers and young children could be secreting the virus through saliva and urine.
• Remember hand washing with soap after activities such as changing diapers, bathing or feeding a baby, 
wiping running nose, touching baby’s toys, or surfaces contaminated by saliva or urine.
• Avoid kissing babies on the mouth, sharing kitchen utensils, toothbrushes, or towels
Table 3. 
Information should be given to all women of reproductive age about simple hygiene measures and change of 
behavior that could prevent seroconversion.
• Treating the condition with oral valganciclovir (16 mg/kg/dose twice a day) for 6 months is now 
considered an effective and well-tolerated therapeutic option for symptomatic neonates, while currently 
evidence of benefit of antiviral therapy in asymptomatic babies is still lacking.
Table 2. 
Antiviral therapy for congenital CMV infection.
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by clinical examination that pass neonatal hearing screening. These babies may 
develop late onset hearing impairment or other neurological sequelae and being 
diagnosed at an early stage by neonatal screening could improve their outcome, 
before it is too late for a successful rehabilitation [46]. Babies with symptomatic 
infection should be readily diagnosed by clinical examination (there should be 
no need for a universal screening in these babies), but sometimes awareness on 
congenital CMV even among health care professionals is relatively low so that too 
often being “small for gestational age” or other signs of possible CMV infection are 
attributed to other conditions and CMV test is not performed [26].
In a study we published in 2014 [47] we found an association between congenital 
CMV infection and preterm births (3.03%), and with SGA condition (3.7%), sug-
gesting that routine CMV urine detection should be at least performed in all babies 
born before 37 weeks of gestational age and in term SGA newborns. Today, we could 
say that both universal screening and targeted screening have shown to be cost-
effective, but the first one provides large net savings and better care [26, 28–29].
None of the benefits of newborn CMV screening will occur if the universal 
screening is not associated with an adequate follow-up program for an early detec-
tion and intervention of hearing loss, visual impairment, and cognitive deficits. 
Only if families are fully informed and never left alone in this journey, but thor-
oughly supported, then the potential parental stress, linked to a universal screening, 
could be outweigh by well-demonstrated advantages of an early diagnosis. But, 
even more important than universal screening is to clearly and thoroughly inform 
pregnant women about what CMV is, how it is transmitted, and how to prevent it: 
early diagnosis is fundamental, but prevention, whereas a vaccination has yet to 
come, is even more fundamental.
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